NEW YORK, Sept. 09, 2016 -- Pomerantz LLP announces that a class action lawsuit has been filed against Quorum Health Corporation (“Quorum” or the “Company”) (NYSE:QHC) and certain of its officers. The class action, filed in United States District Court, Middle District of Tennessee, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Quorum securities: (1) pursuant and/or traceable to Quorum’s false and misleading Registration Statement issued in connection with the Company’s spinoff from Community Health Systems, Inc. (“CHS”) effective on or about April 29, 2016; and/or (2) on the open market between May 2, 2016 and August 10, 2016, both dates inclusive, seeking to recover compensable damages caused by Defendants’ violations of the Securities Act of 1933 (the “Securities Act”) and the Securities Exchange Act of 1934 (the “Exchange Act”).
If you are a shareholder who purchased Quorum securities during the Class Period, you have until November 8, 2016 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.
[Click here to join this class action]
Quorum is an independent operator and manager of general acute-care hospitals and outpatient services in the United States, with facilities in 16 states. Quorum was spun off from CHS effective April 29, 2016. Under the terms of the spin-off, CHS stockholders who held CHS common stock as of April 22, 2016, the record date, received a distribution of one share of Quorum common stock for every four shares of CHS common stock, plus cash in lieu of any fractional shares. CHS’s stockholders owned all of the outstanding common stock of Quorum upon completion of the spinoff.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) a number of Quorum’s hospitals were underperforming at the time of the spin-off from CHS; (ii) various other indicators of impairment existed at the time of Quorum’s spin-off from CHS; (iii) Quorum disregarded and/or failed to advise investors of the foregoing issues; and (iv) as a result of the foregoing, Quorum’s public statements were materially false and misleading at all relevant times.
On August 10, 2016, Quorum issued a press release and filed a Quarterly Report on Form 10-Q with the SEC announcing the Company’s financial and operating results for the three months ended June 30, 2016 (the “Q2 2016 10-Q”). In the press release and Q2 2016 10-Q, Quorum reported a substantial net loss and an operating loss for the quarter. Defendants blamed the large operating loss on the $250.4 million in impairment charges Quorum had taken in the quarter, including $45.4 million to reduce certain long-lived asset values in property, equipment and software; $5 million in goodwill based on management’s decision to divest certain hospitals; and $200 million related to the carryover allocation of goodwill at the time of the spin-off from CHS.
On this news, Quorum’s share price fell $4.99, or 49.8%, to close at $5.03 on August 11, 2016.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT: Robert S. Willoughby Pomerantz LLP [email protected]


Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Apple Turns 50: From Garage Startup to AI Crossroads
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 



